The Division of Surgical Oncology and Endocrine Surgery participates in five multidisciplinary disease management programs: Breast Diseases, Endocrine Disorders, Gastrointestinal Malignancies, Melanoma and Cutaneous Malignancies, and Sarcoma and Soft Tissue Tumors. The clinical practice in these areas has grown significantly over the past few years, largely due to the addition of several outstanding faculty members.
Endocrine Surgery Center
The goal of the Vanderbilt Endocrine Surgery Center is to provide the best overall care for individuals with problems related to the endocrine system (the thyroid gland, parathyroid glands, adrenal glands, and pancreas).
Our newly established Neuroendocrine Center was the first facility in the U.S. to use the 68Gallium-DOTATATE PET/CT scan that offers the highest resolution and sensitivity in locating tumors. Our goal is to offer our patients the comfort and security of knowing that we can see much more with this scan, and then surgically remove all tumors, not just some of them.
The Division of Surgical Oncology at Vanderbilt has quietly become the primary force for acquiring and banking cancerous tissue samples, a vital first step in the delivery of personalized medicine. With these samples, researchers can begin the process of determining what molecules or markers drive tumor growth. From there, therapies that block activation of these markers can be developed. Recently, Vanderbilt’s Division of Surgical Oncology was one of only three institutions that partnered with a biotech company to develop a drug that specifically binds to the BRAF molecule in melanoma, which activates tumor growth. Such targeted drug design offers the promise of the right drug, to the right patient, at the right time.